A5088531207- Biosimilars and Bioanalytical Methods
- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Erythropoietin and Anemia Treatment
- Inflammatory Bowel Disease
- Psoriasis: Treatment and Pathogenesis
- Pharmaceutical studies and practices
- Pharmacovigilance and Adverse Drug Reactions
- Statistical Methods in Clinical Trials
- Atrial Fibrillation Management and Outcomes
- Hidradenitis Suppurativa and Treatments
- Chronic Kidney Disease and Diabetes
- Drug-Induced Adverse Reactions
- Tuberculosis Research and Epidemiology
- Rheumatoid Arthritis Research and Therapies
- Chemotherapy-related skin toxicity
- Diabetes Treatment and Management
- Blood disorders and treatments
- Inflammatory mediators and NSAID effects
- Melanoma and MAPK Pathways
- Colorectal and Anal Carcinomas
- Potassium and Related Disorders
- Autoimmune and Inflammatory Disorders
- Magnesium in Health and Disease
- Spondyloarthritis Studies and Treatments
University of Verona
2022-2025
University of Messina
2014-2024
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
2016-2023
Erasmus MC
2021
To date, no population-based studies have specifically explored the external validity of pivotal randomized clinical trials (RCTs) biologics simultaneously for a broad spectrum immuno-mediated inflammatory diseases (IMIDs). The aims this study were, firstly, to compare patients' characteristics and median treatment duration approved IMIDs between RCTs' real-world setting (RW); secondly, assess extent biologic users treated in that would not been eligible inclusion into RCT each indication...
Background Non-steroidal anti-inflammatory agents (NSAIDs) are known to be associated with renal damage. No clear evidence exists regarding differential risk of chronic kidney disease (CKD), specifically, across various NSAIDs. Aim The aim this population-based case-control study was evaluate the association between use individual NSAIDs and CKD in a general population Southern Italy. Methods A nested carried out using practice Arianna database, identifying incident patients as cases matched...
Background The use of nephrotoxic drugs can further worsening renal function in chronic kidney disease (CKD) patients. It is therefore imperative to explore prescribing practices that negatively affect CKD Aim To analyze the patients a general population Southern Italy during years 2006–2011. Methods practice “Arianna” database contains data from 158,510 persons, registered with 123 practitioners (GPs) Caserta. were identified searching: CKD-related ICD-9 CM codes among causes...
The advent of Immune Checkpoint Inhibitors (ICIs) as a standard care for several cancers, including melanoma and head/neck squamous cell carcinoma has changed the therapeutic approach to these conditions, drawing at same time attention on some safety issues related their use. To assess incidence psoriasis specific immune-related cutaneous adverse event attributing ICIs using Eudravigilance reporting system. All reports drug reactions (ADRs) concerning either exacerbation or de novo onset...
Purpose: This research aimed to develop and validate a META-algorithm combining individual immune-mediated inflammatory disease (IMID)-specific algorithms identify the exact IMID indications for incident biological drug users from claims data within context of Italian VALORE project. Methods Patients: All subjects with at least one dispensing TNF-alpha inhibitors, anti-interleukin agents, selective immunosuppressants approved IMIDs were identified databases Latium region in Italy...
To explore the prescription patterns of erythropoiesis-stimulating agents (ESAs) in four large Italian geographic areas, where different health policy interventions to promote biosimilar use routine care are undertaken.A retrospective drug utilization study was conducted during years 2009-2013. The data sources were administrative databases Tuscany region and Caserta, Palermo, Treviso Local Health Units (LHUs). characteristics, prevalence, switching ESAs (biosimilars reference products),...
Biological drugs have improved the management of immune-mediated inflammatory diseases (IMIDs) despite being associated with important safety issues such as immunogenicity, infections, and malignancies in real-world settings.The aim this study was to explore potential a large Italian multi-database distributed network for use postmarketing surveillance biological drugs, including biosimilars, patients IMID.A retrospective cohort conducted using 13 regional claims databases during 2010-2019....
Background Switch patterns among different biologics and from originators to biosimilars (and vice versa) can be complex in patients with psoriasis (PsO) psoriatic arthritis (PsA).
Background Since 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Italian market. Very limited post-marketing data exist comparative effectiveness biosimilar and originator ESAs. Aim This population-based study was aimed to compare effects biosimilars, reference product other ESAs still covered by patent hemoglobinemia in chronic kidney disease (CKD) cancer patients a Local Health Unit (LHU) from Northern Italy. Methods A retrospective cohort conducted during...
Real-world data on the comparative effectiveness and safety of switching among different epoetins (including originators biosimilars) are limited. In light current debate about interchangeability, prescribers, some patient groups decision makers calling for additional post-marketing evidence clinical effects between originator biosimilar in chronic kidney disease (CKD) patients. The objective this study was to evaluate versus non-switching from originator/biosimilar epoetin alpha (ESA α) any...
Evidences show that around 20% of biosimilar or originator erythropoiesis-stimulating agents (ESAs) users are hyporesponsive. Controversial post-marketing data exist on the predictors ESA hyporesponsiveness. The aim this study was to identify hyporesponsiveness in patients with chronic kidney disease (CKD) cancer clinical practice.During years 2009-2015, a multi-center, population-based, cohort conducted using claims databases Treviso and Caserta Local Health Units (LHUs). All incident were...